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The Marburg virus (MBGV) nucleocapsid complex is composed of four viral proteins (NP, L, VP35, and VP30) and the
negative-strand nonsegmented genomic RNA. NP, L, and VP35 are functionally conserved among the order Mononegavirales,
whereas VP30, a phosphoprotein, represents a filovirus-specific nucleocapsid protein. In the present paper, we have
characterized the localization and function of VP30 phosphorylation. The main phosphorylation sites are represented by
seven serine residues in the region of amino acid 40 to 51 of VP30. Additionally, trace amounts of phosphothreonine were
detected. Substitution of serine residues 40 and 42 by alanine abolished the interaction of VP30 with NP-induced inclusion
bodies, which contain nucleocapsid-like structures formed by NP. Substitution of the other phosphoserine residues had little
effect on this interaction. Replacement of the introduced alanine residues 40 and 42 by aspartate restored the interaction
between VP30 and the NP inclusions pointing to the importance of negative charges at these particular positions. © 2001
Academic PressINTRODUCTION
Marburg virus (MBGV) and the closely related Ebola
virus (EBOV) make up the family Filoviridae, which to-
gether with the Paramyxoviridae, Rhabdoviridae, and
Bornaviridae constitutes the order Mononegavirales.
Filoviruses are highly pathogenic for humans and non-
human primates, causing a severe hemorrhagic fever
with high fatality rates (for reviews see Martini and Sieg-
ert, 1971; Pattyn, 1978). The emerging potential of filovi-
ruses is underlined by several outbreaks during the last
6 years (WHO, 1995, 1999, 2001). Several attempts have
been made to detect the natural reservoir of filoviruses
with hitherto no success (Breman et al., 1999; Leirs et al.,
1999). The prototype of Filoviridae, MBGV, was isolated in
1967, when several laboratory workers were infected
after contact with imported monkeys (Siegert et al., 1967).
The enveloped MBGV particles are composed of
seven structural proteins and the RNA genome. Four viral
proteins are the components of the nucleocapsid: the
nucleoprotein NP (Becker et al., 1998; Kolesnikova et al.,
2000; Lo¨tfering et al., 1999; Sanchez et al., 1992), the L
protein (Mu¨hlberger et al., 1992), VP35 (Mu¨hlberger et al.,
1998), and VP30 (Becker et al., 1998). VP40 and VP24 are
located between the envelope and the nucleocapsid and
probably represent viral matrix proteins (Becker et al.,
1 To whom correspondence and reprint requests should be ad-
ressed at Institut fu¨r Virologie der Philipps-Universita¨t Marburg, Rob-
rt-Koch-Str. 17, 35037 Marburg, Germany. Fax: 116421-2865482. E-
ail: becker@mailer.uni-marburg.de.1711998). The envelope of MBGV is decorated by the only
surface protein, GP, which is inserted into the viral mem-
brane as a homotrimer (Feldmann et al., 1991). Since GP
is the only surface protein of MBGV, it is assumed to be
responsible for virus entry into host cells (Becker et al.,
1995) and to be the major target for the immune re-
sponse of the infected organism. Thus, it has been
shown for MBGV and EBOV that immunization against
the respective surface protein was sufficient to protect
guinea pigs and monkeys for a challenge infection
(Hevey et al., 1998; Sullivan et al., 2000).
MBGV infection of target cells is characterized by the
formation of typical inclusion bodies which contain the
nucleocapsid proteins (Becker et al., 1998). Formation of
the inclusion bodies is induced by the major nucleocap-
sid protein, NP, which forms nucleocapsid-like tubular
structures resembling the core structure of nucleocap-
sids in MBGV-infected cells (Kolesnikova et al., 2000). It
was further shown that NP is the central player in com-
plex formation between the nucleocapsid proteins. NP
interacts with itself and VP35 and builds a trimeric com-
plex with L via VP35. Additionally, NP was found to
interact with VP30 (Becker et al., 1998).
VP30 is encoded by the fifth gene of MBGV, which is
placed between the GP gene and the gene coding for
VP24 (MBGV gene order: 39-NP-VP35-VP40-GP-VP30-
VP24-L-59). This genome organization is unusual since
most viruses of the order Mononegavirales encode their
nucleocapsid proteins by the first (NP or N), second (P),
and last gene (L). The VP30 gene is 1249 nt in length and
codes for a protein of 281 amino acids. VP30, as its EBOV0042-6822/01 $35.00
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172 MODROF ET AL.counterpart, is a phosphoprotein (Becker and Mu¨hl-
berger, 1999; Elliott et al., 1985).
The role of phosphorylation in the regulation of essen-
tial functions of cellular proteins by the reversible attach-
ment of negative charges is well established. Also, many
viruses exploit cellular protein kinases and phospha-
tases to regulate the function of their own proteins. In
this paper, we have determined the localization of the
phosphorylation sites of MBGV VP30. Subsequently, we
have characterized the function of VP30 phosphorylation
for the formation of the VP30/NP complex.
RESULTS
Treatment of VP30 with alkaline phosphatase
Recently, we have shown that MBGV VP30 is phos-
phorylated (Becker and Mu¨hlberger, 1999). As a first
approach to further characterize this posttranslational
modification, we investigated whether (i) the phosphor-
ylation was sensitive to alkaline phosphatase (CIP) and,
if so, whether (ii) phosphorylated and dephosphorylated
VP30 displayed a different migration pattern in SDS–
PAGE. To this end, MBGV particles were purified from the
supernatant of MBGV-infected C1008 cells which were
previously metabolically labeled with either [32Pi] or
35S]Promix. Isolated particles were treated with 1% SDS
nd boiled, and VP30 was immunoprecipitated from the
ysates. The immune complexes were incubated with
IP to remove the attached phosphate groups and were
inally separated on SDS–PAGE. The gels were dried
nd the radioactive signals were visualized using a Bio-
mager. 32P-labeled VP30 migrated at 34 kDa as a rela-
tively diffuse band (Fig. 1, lane 4). CIP treatment resulted
in an almost complete disappearance of the radioactive
FIG. 1. Phosphatase treatment of VP30. MBGV VP30 (left, lanes 1–4):
C1008 cells were infected with MBGV and metabolically labeled with
[32Pi] or [
35S]Promix at 4 days p.i. Virions were purified from the super-
natant of the cells and treated with 1% SDS. VP30 was immunoprecipi-
tated from the lysate using a guinea pig anti-VP30 antiserum (dilution
1:250) and either treated with CIP or left untreated (2). The samples
were separated by SDS–PAGE and gels were dried and exposed to
BioImager plates. Recombinant VP30 (right, lanes 5–12): 5 3 105 sub-
confluent HeLa cells were infected with MVA-T7 and subsequently
transfected with 1 mg of the plasmid pGEM-VP30. At 14–16 h p.i., cells
were metabolically labeled with either [32Pi] or [
35S]Promix, and VP30
was immunoprecipitated and treated as described above. MBGV, viri-
on-associated VP30; VP30, recombinant VP30 immunoprecipitated
from HeLa cell lysates; MVA-T7, HeLa cells infected with MVA-T7; Mock,
HeLa cells, mock-infected; (1), CIP-treated; (2), not treated with CIP.signal, demonstrating that most of the incorporated fphosphate groups were sensitive to phosphatase (Fig. 1,
lanes 3 and 4). A faint remaining signal in the CIP-treated
sample migrated at 33 kDa (lane 3). The [35S]Promix-
labeled VP30 migrated in SDS–PAGE as a diffuse band at
33–35 kDa (lane 1). After digestion with CIP, the diffuse
band disappeared and two discrete bands at approxi-
mately 33 and 35 kDa were detectable (lane 2). These
bands were also faintly visible in the nontreated sample
(lane 1, arrows). Quantification of the signal strengths of
the upper and lower bands revealed that the ratio be-
tween the two signals was changed after dephosphory-
lation. In comparison to the 35kDa band, the signal of the
lower band became stronger (quantification not shown).
It is concluded that (i) phosphorylation of VP30 leads to
a slightly altered migration of the protein in SDS–PAGE
and (ii) additional to the phosphorylated VP30, nonphos-
phorylated VP30, is incorporated into the virions. The
nature of the 35-kDa form is still unknown.
To investigate whether the recombinant VP30 was
phosphorylated as well, the protein was expressed in
HeLa cells using the vaccinia virus–T7 system. HeLa
cells were infected with MVA–T7 and subsequently
transfected with pGEM-VP30, a plasmid encoding VP30
under the control of the T7 promoter. At 8–12 h p.i., cells
were metabolically labeled with [32Pi] or [
35S]Promix, and
VP30 was immunoprecipitated using a guinea pig anti-
VP30 antiserum. Immune complexes were incubated
with CIP and further treated and detected as described
above. Figure 1 shows that [32Pi]- and [
35S]Promix-la-
beled VP30 appeared as a diffuse band migrating at
33–34 kDa (lanes 5–8). Dephosphorylation of the 32Pi-
labeled recombinant VP30 led to the removal of phos-
phate groups which is demonstrated by the reduced
strength of the radioactive signal and the molecular
weight shift of the protein to 33 kDa (lane 7). However,
the dephosphorylation was not complete (Fig. 1, lanes 7
and 8). Taken together, the recombinant VP30 is phos-
phorylated similar to the virion-associated VP30 and
was, thus, available for further analysis.
Phosphoamino acid analysis
The type of phosphoamino acids within VP30 was
determined using 2D thin-layer chromatography electro-
phoresis. Either virion-associated or recombinant VP30
was metabolically labeled with 32Pi, immunoprecipitated,
nd partially hydrolyzed with hydrochloric acid. The hy-
rolysates were mixed with standard phosphoamino ac-
ds, spotted onto thin layer plates, and electrophoresed
n two dimensions (Fig. 2). Quantification of the radioac-
ive signals and comparison with the ninhydrine signals
f the standard phosphoamino acids revealed the stron-
est signal for phosphoserine, which was accompanied
y a small amount of phosphothreonine. The ratio be-
ween phosphoserine and phosphothreonine was 26:1
or the recombinant VP30 (left). This ratio was deter-
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173PHOSPHORYLATION OF MARBURG VIRUS VP30mined to be 10:1 for the virion-associated VP30 (right).
This shift toward phosphothreonine might suggest that a
special form of phosphorylated VP30 is favored for in-
corporation into progeny virions. Investigations to clarify
this question are underway.
Formic acid treatment: N-terminal phosphorylation
It was then of interest to localize the phosphorylation
site(s) in VP30. At first, the FLAG-tagged VP30 was ex-
pressed using the vaccinia virus-T7 system as described
above, metabolically labeled with [32Pi] or [
35S]Promix,
mmunoprecipitated, and treated with formic acid to
leave the protein between aspartate 89 and proline 90,
he only site of VP30 where cleavage could take place at
H 2.5. Proteolytic fragments were separated on SDS–
AGE, and radioactive signals were visualized using a
ioImager. Since only the N-terminal fragment of VP30
as labeled with 32Pi, it was suggested that VP30 is
mainly phosphorylated in the 89 amino acids of the
N-terminus (data not shown).
Phosphorylation state analysis of VP30 deletion
mutants
To determine the localization of phosphate acceptor
sites in VP30 more precisely, N- and C-terminal deletion
mutants of VP30 were constructed dividing the molecule
in two halves. At first a deletion mutant of VP30 was
analyzed encompassing amino acids 152–281. However,
this mutant turned out to be unstable upon expression in
HeLa cells. Thus, a fusion protein was constructed con-
taining the FLAG-tagged 500 N-terminal amino acids of
the MBGV L protein fused to the C-terminus of VP30 (Fig.
FIG. 2. Phosphoamino acid analysis of VP30. Virion-associated (M
urified as described under Fig. 1. Immune complexes were separated
and was cut out. The protein was partially hydrolyzed with hydrochlo
ample was then spotted onto thin-layer plates and chromatographed in
nd the positions of the standard phosphoamino acids were marked.
hosphoamino acids. VP30, recombinant VP30 purified from MVA-infect
urified from MBGV structural proteins; PS, phosphoserine; PT, phosp3A, LN-term/VP30152–281). To verify that the N-terminus of L onne hand was not phosphorylated and on the other hand
id not prevent phosphorylation of the fused fragment,
dditional mutants were constructed, expressing either
he L N-terminus (LNterm) alone or the L N-terminus fused
o the full-length VP30 (LNterm/VP301–281). The mutants were
expressed in HeLa cells using the vaccinia virus–T7
system, metabolically labeled with [32Pi] or [
35S]Promix,
immunoprecipitated, and separated by SDS–PAGE. The
radioactive signals were visualized with a BioImager and
quantified using the Raytest TINA software. Phosphory-
lation state analysis of these mutants showed that, as
expected, the N-terminus of L was neither phosphory-
lated nor inhibitory for the phosphorylation of the fused
full-length VP30 (data not shown). Examination of the
mutant which contained the C-terminus of VP30 fused to
the L N-terminus (LN-term/VP30151–281) revealed that this
protein was not phosphorylated (data not shown). These
data underlined the previous findings that phosphoryla-
tion of VP30 did not take place in the C-terminus.
To further narrow down the phosphorylated site(s) in
the N-terminus, deletion mutants of VP30 were con-
structed dividing the region of amino acid 1–151 (Fig. 3A,
VP301–40, VP301–67, VP301–151, and VP3068–151). The mutants
and VP30 wild-type were expressed in HeLa cells using
the vaccinia virus–T7 system as described above. Phos-
phorylation state analysis revealed that the full-length
VP30 and the N-terminal mutant (VP301–151) were phos-
phorylated (Fig. 3B, lanes 5–8). The mutant containing
only amino acids 68–151 was not phosphorylated point-
ing to amino acids 1–67 as the main phosphorylated
region (Fig. 3B, lanes 9 and 10). This was further under-
lined by the analysis of the mutants VP301–40 and
ght) or recombinant VP30 (VP30, left) was metabolically labeled and
S–PAGE and blotted onto Immobilon membrane and the VP30-specific
and resuspended in a mixture of standard phosphoamino acids. The
mensions. Plates were subsequently sprayed with ninhydrine solution,
tes were then exposed to a BioImager plate to detect the radioactive
transfected HeLa cells; MVA-T7; MVA-infected HeLa cells; MBGV, VP30
nine; PY, phosphotyrosine.BGV, ri
by SD
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174 MODROF ET AL.32Pi-labeled proteins, which were normalized by the
[35S]Promix-labeled expression control, showed that the
irst 67 amino acids contained almost the whole phos-
hor label of VP30 (Fig. 3C, lanes 1 and 2), whereas the
hosphorylation of VP301–40 was greatly reduced (6% of
he mutant VP301–67, Fig. 3C, lanes 3 and 4).
Taken together, these experiments demonstrated that
FIG. 3. Phosphorylation state analysis of VP30 deletion mutants. (A
ubscript refer to the amino acids of VP30 present in the respective mu
s indicated. (B) and (C) Phosphorylation state of VP30 deletion mutan
f the respective plasmids encoding either VP30 wild-type or VP30 dele
P30 and the VP30 mutants were immunoprecipitated using a guinea
omplexes were separated on SDS–PAGE; gels were dried and exposthe main phosphorylation sites of VP30 were located inthe N-terminus between amino acid 40 and 67. Thus, the
following analyses focused on this region.
Substitution mutants of serine residues in the region
of amino acid 40 to 67
Sequence analysis of VP30 revealed seven serine
residues in the region of amino acid 40–67 which were
atic representation of the employed VP30 mutants. The numbers in
the right-hand side, the phosphorylation state of the respective mutant
105 HeLa cells were infected with MVA-T7 and transfected with 1 mg
tants. Cells were metabolically labeled as described under Fig. 1, and
ti-VP30 antiserum (dilution 1:250) and protein A-Sepharose. Immune
BioImager plate. S, [35S]Promix-labeled VP30; P, 32Pi-labeled VP30.) Schem
tant. At
ts. 5 3
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175PHOSPHORYLATION OF MARBURG VIRUS VP30clustered between amino acids 40 and 51 (Fig. 4, above
lane 1). We constructed a set of FLAG-tagged full-length
mutants of VP30 by substituting groups of serine resi-
dues with alanine residues (Fig. 4). The mutants were
expressed using the vaccinia virus–T7 system, metabol-
ically labeled, immunoprecipitated, separated by SDS–
PAGE, and analyzed using a BioImager as described
above. Metabolic labeling of the mutants with [35S]Pro-
mix was used to normalize the signals of 32Pi labeling
not shown). When all of the seven serine residues in the
mino acid region 40 to 51 were changed to alanine, the
adioactive signal was decreased by 80% compared to
he wild-type of VP30 (Fig. 4, lanes 1 and 2). Substitution
f the serine residues in the region 40–46 or in the region
7–51 to alanine resulted in both cases in a reduction of
he signal strength to approximately 50% (Fig. 4, lanes 3
nd 4). Substitution of three serines at positions 43, 46,
nd 51, which are located in conserved protein kinase
ecognition sites, lowered the phosphorylation signal by
0% compared with the wild-type (Fig. 4, lanes 1 and 5).
hese results point to the fact that most if not all of the
erine residues in the amino acid region 40–51 were
argets for cellular kinases.
unctional significance of the phosphorylation of
erine residues 40 and 42
It was shown previously that MBGV VP30 interacted
ith the major nucleocapsid protein NP (Becker et al.,
FIG. 4. Phosphorylation state analysis of amino acid region 40–51 in
VP30. 5 3 105 subconfluent HeLa cells were infected with MVA-T7 and
ransfected with 1 mg of each plasmid encoding VP30 wild-type or VP30
ubstitution mutants which contained serine-to-alanine exchanges in
he amino acid region 40–51. Cells were metabolically labeled with
32Pi], and VP30 and the VP30 mutants were immunoprecipitated using
a guinea pig anti-VP30 antiserum (dilution 1:250) and protein A-Sepha-
rose. Immune complexes were separated by SDS–PAGE and gels were
exposed to a BioImager plate. The amino acid sequence of VP30
(40–51) is given above lane 1. For the mutants, only the respective
serine to alanine substitutions are indicated.998). NP is the main determinant of the nucleocapsidomplex which forms, upon recombinant expression, in-
racellular inclusions. These inclusions contain accumu-
ated tubular structures which resemble the core nucleo-
apsids formed in the cytoplasm of MBGV-infected cells
Kolesnikova et al., 2000). When coexpressed with NP,
he otherwise homogeneously distributed VP30 is redis-
ributed into the NP-induced inclusions (Becker et al.,
998). It was of interest whether the phosphorylation of
P30 might have an impact on this protein–protein inter-
ction. VP30 or phosphorylation-deficient VP30 mutants
ere, thus, coexpressed together with NP using the
accinia virus–T7 system and cells were subjected to
mmunofluorescence analysis.
As expected, VP30 wild-type colocalized with NP in the
P-induced inclusion bodies when the two proteins
ere coexpressed (Fig. 5A; Becker et al., 1998). Coex-
ression of the mutants VP30S40–51A or VP30S40–46A with NP,
however, showed a different pattern. Whereas NP is still
found in the inclusion bodies, VP30 is now homoge-
neously distributed and, in some cells, concentrated
around the inclusion bodies (Figs. 5B and 5C). Two other
mutants, VP30S47–51A and VP30S43,46,51A, showed the wild-
type pattern when coexpressed with NP (Figs. 5D and
5E). Since the latter two mutants had in common that
they both contained serine residues at positions 40 and
42, it was presumed that possibly these two residues
were particularly critical for the interaction with NP in-
side the inclusions. Therefore, VP30 mutants were con-
structed where the serine residues at position 40 and 42
were either separately or together substituted by alanine
(VP30S40A, VP30S42A, and VP30S40,42A). Phosphorylation
tate analysis of the mutant VP30S40,42A, with both serines
replaced by alanine, showed a reduction of the phos-
phorylation by approximately 40% (not shown). When
either serine 40 or serine 42 was replaced, phosphory-
lation of the respective mutants was only slightly im-
paired (not shown). These results suggested that the two
serine residues could alternatively be phosphorylated
and only the replacement of both impaired the overall
phosphorylation of VP30. To investigate the effect of the
missing serine residues at amino acid position 40 and/or
42 on the interaction with NP, the three mutants were
coexpressed together with NP using the vaccinia vi-
rus–T7 system as described above and subjected to
immunofluorescence analyses (Figs. 5F-5H). It is shown
that the exchange of serines 40 and 42 obviously
blocked the redistribution of VP30 into the NP-induced
inclusions (Fig. 5F). Substitution of either serine 40 or 42
alone only partly inhibited the interaction with NP (Figs.
5G and 5H). The respective mutants VP30S40A and
VP30S42A are predominantly located inside or at the rim of
the inclusions and, to a lesser extent, distributed homo-
geneously in the cytosol. It is therefore concluded that
serine residues 40 and 42 together are essential for the
interaction between NP inclusions and VP30.Since the altered phenotype of the mutant VP30S40,42A
m
t
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176 MODROF ET AL.could have been the result of the missing serine resi-
dues rather then the missing phosphorylation of the
amino acids, we mimicked the negative charges of the
phosphate groups at serines 40 and 42 by replacing the
two amino acids either singly or in combination to as-
partate (Figs. 5I-5K). When single aspartates were intro-
duced, the other serine residue was changed to alanine.
It was found that, indeed, substitution of amino acids 40
and 42 to aspartate revealed almost the same distribu-
tion pattern as the VP30 wild-type (Fig. 5I). The substitu-
tion of only one of the serines residues, either S40 or S42,
by aspartate was not sufficient to support the redistribu-
tion of VP30 into the inclusions (Figs. 5J and 5K). These
results emphasize the importance of negative charges at
amino acid position 40 and 42 for the interaction of VP30
with the NP-induced nucleocapsid-like structures.
Immunoelectron microscopy
Finally, the distribution of VP30 wild-type and one of
FIG. 5. Influence of serine residues 40–51 on colocalization of VP30
with plasmids encoding the FLAG-tagged VP30 wild-type or the FLAG-t
of MBGV. The transfected amounts of the plasmids encoding VP30 mu
pTM-VP30, 10 ng; pTM-VP30S40–51A, 40 ng; pTM-VP30S40–46A, 40 ng; pTM-
At 16 h p.i., cells were fixed with 3% PFA and permeabilized using 0.2
analysis using a mouse monoclonal anti-NP antibody (dilution 1:25) a
detected with a FITC-labeled donkey anti-rabbit serum (Dianova, diluti
1:100).the mutants which was unable to interact with the NPinclusions (VP30S40,42A) were analyzed by immunoelectron
icroscopy to confirm the colocalization of VP30 wild-
ype and NP inside the inclusions and to investigate the
ocalization of the mutant. VP30 or the mutant VP30S40,42A,
both containing FLAG epitopes at the N-terminus, were
expressed in HeLa cells together with NP as described
above. The cells were harvested at 16 h p.i. and cell
pellets were embedded in LR gold for immunogold la-
beling. Subsequently, ultrathin sections were prepared
which were used for immunostaining. VP30 and
VP30S40,42A were labeled with gold particles of a diameter
of 10 nm, and NP was labeled with 6-nm gold particles.
Figure 6A shows a part of an inclusion in cells express-
ing VP30 and NP. Both proteins colocalized inside the
inclusion (black arrows: VP30, arrowheads: NP). Inclu-
sion bodies in cells expressing NP and VP30S40,42A, how-
ever, showed a different pattern. Here, VP30S40,42A (black
arrows) was detected primarily homogeneously in the
cytoplasm (not shown) or at the periphery of the inclu-
inclusions. HeLa cells were infected with MVA-T7 and cotransfected
VP30 substitution mutants together with 100 ng of pT-NP, encoding NP
as varied according to the expression rates of the respective mutants.
–51A, 400 ng; pTM-VP30S43,46,51A, 400 ng. VP30 mutants in F to K: 100 ng.
n X-100. Subsequently, cells were subjected to immunofluorescence
bbit anti-FLAG serum (Zymed, dilution 1:50). Bound antibodies were
0) and a rhodamine-labeled goat anti-mouse serum (Dianova, dilutionand NP
agged
tants w
VP30S47
% Trito
nd a ra
on 1:10sions, suggesting that VP30S40,42A is targeted to the inclu-
s
a
(
177PHOSPHORYLATION OF MARBURG VIRUS VP30sion but could not interact with the NP inside (arrow-
heads, Fig. 6B).
DISCUSSION
In the present paper, we have characterized the local-
ization and function of the phosphorylation of MBGV
VP30. In contrast to EBOV VP30, which acts as an EBOV-
specific transcription activator, MBGV VP30 is not essen-
tial for viral transcription (Mu¨hlberger et al., 1998). Al-
though MBGV VP30 was able to partially replace EBOV
VP30 in its function to activate EBOV transcription, the
role of MBGV VP30 in the homologous system remains
obscure (Mu¨hlberger et al., 1999).
We earlier presented evidence that VP30 is a phos-
phoprotein (Becker and Mu¨hlberger, 1999), and we have
shown here that the major phosphorylation sites of VP30
are represented by seven serine residues in the region
of amino acids 40 to 51 whose exchange to alanine
reduced the phosphorylation of VP30 by 80%. The re-
maining phosphorylation of this mutant is most probably
caused by phosphothreonine, which is suggested by the
performed phosphoamino acid analysis. The exact local-
ization of this phosphothreonine residue(s) is not yet
FIG. 6. Immunoelectron microscopic analysis of the interaction betwe
infected with MVA-T7 and cotransfected with plasmids encoding the
together with pTM-NP (2.5 mg) encoding NP of MBGV. At 16 h p.i., cells w
ections of the cells were incubated with a 1:100 dilution of rabbit serum
gainst NP. Subsequently, sections were incubated with a 1:30 dilution
10-nm gold particles) antibodies. (A) Cells transfected with VP30 wilddetermined.The phosphoserines in amino acid region 40 to 51 are
only partly located in conserved recognition sites of
known protein kinases. Serine 43 is located in a con-
served protein kinase C site, serine 46 in a protein
kinase CKII site, and serine 51 might be suitable for a
proline-dependent kinase similar to the mitogen-acti-
vated protein kinases (Davis, 1993). Exchange of these
three serines to alanines decreased the phosphorylation
of VP30 only by 30%. Thus, our data point to additional
unidentified protein kinases with different recognition
motifs which are involved in VP30 phosphorylation. Sub-
stitution of serine residues 40–46 or 47–51 to alanine
reduced the phosphorylation of VP30 by approximately
50%, respectively, showing that serine residues of the
whole region might be targets for protein kinases. This is
further supported by computer-based analysis, which
predicted with high-probability values (.0.9, data not
shown) that all serine residues 40, 42, 43, 46, 47, 50, and
51 might act as phosphate acceptor sites (Program Net-
Phos II, Blom et al., 1999).
Multisite phosphorylation, as it takes place with VP30,
has also been detected in MBGV NP and several other
viral and cellular proteins (Lo¨tfering et al., 1999, for re-
0 and NP inside the inclusions. 1.5 3 106 subconfluent HeLa cells were
tagged VP30 wild-type (250 ng) or FLAG-tagged VP30S40,42A (250 ng)
d with 3% PFA and further processed for electron microscopy. Ultrathin
t the FLAG epitope and a 1:10 dilution of a mouse monoclonal antibody
-labeled anti-mouse (6-nm gold particles) and gold-labeled anti-rabbit
nd NP. (B) Cells transfected with VP30S40,42A and NP. Bar, 100 nm.en VP3
FLAG-
ere fixe
agains
of gold
-type aview see Cohen, 2000). Phosphorylation of different ac-
178 MODROF ET AL.ceptor sites might have an antagonistic effect, as it was
shown for the activation of cdc2 (Hoffmann et al., 1993).
In other cases, such as the MAPKAP kinase-2, cooper-
ative phosphorylation of multiple acceptor sites was the
prerequisite for a fully active protein (Ben-Levy et al.,
1995). Multiple phosphorylation has also been observed
for the P protein of VSV, the cofactor of the viral polymer-
ase L. The sequential phosphorylation by two cellular
protein kinases was necessary to fully phosphorylate the
protein. Phosphorylation by protein kinase CKII was es-
sential for the multimerization of P and its function in viral
transcription. The subsequent phosphorylation occurring
in the C-terminus is discussed to regulate viral replica-
tion (Gao and Lenard, 1995).
We have previously described that intracellular inter-
action between VP30 and NP resulted in the relocaliza-
tion of the otherwise homogeneously distributed VP30
into NP-induced inclusions (Becker et al., 1998). In the
present paper we were able to show that this relocaliza-
tion of VP30 is dependent on negative charges at amino
acid positions 40 and 42, which are represented by
phosphoserines. Exchange of these two serine residues
to alanine residues destroyed the interaction between
VP30 and NP inside the NP-induced inclusions. Replac-
ing the introduced alanine residues with the negatively
charged aspartate restored the interaction between
VP30 and NP, and VP30 was again found within the
inclusions. It is therefore concluded that rather the phos-
phorylation of the amino acids at position 40 and 42 and
not the serine residues themselves are critical for the
redistribution of VP30 into the NP-induced inclusions.
The more C-terminally located serine residues (amino
acid position 43, 46, 47, 50, and 51), which are also
subjected to phosphorylation, seemed to be less impor-
tant for this particular function.
NP inside the inclusions is organized in tightly packed
helical nucleocapsid-like structures. In electron micro-
scopic analysis, the NP helices appeared either as hex-
agonally arranged circles (cross section), or as tubular-
like structures (longitudinal section), or, more often, as a
reticular network (skewed section) (Kolesnikova et al.,
2000). It is presumed that these NP helices, which can
also be detected in MBGV-infected cells, represent the
precursors of mature nucleocapsids. These are assem-
bled by recruiting additional viral proteins, i.e., the other
nucleocapsid proteins (VP30, VP35, and L), and possibly
the matrix proteins VP40 and VP24. Consequently, the
electron density of the nucleocapsids is increased. The
mature nucleocapsids which are characterized by their
high electron density (Kolesnikova et al., 2000) are pre-
sumed to be released from the inclusions, transported to
the cell surface, and enwrapped with a lipid bilayer
consisting of the plasma membrane with the inserted
viral surface protein GP. In this scenario, the redistribu-
tion of VP30 into the NP-induced inclusions which was
observed upon coexpression of NP and VP30 most likelyreflects the interaction of the protein with NP helices.
This interaction corresponds to the nucleocapsid matu-
ration in MBGV-infected cells. It is thus concluded that
one prerequisite for the maturation of MBGV nucleocap-
sids is the phosphorylation of serine residues 40 and 42
of VP30.
The only other viruses in the order Mononegavirales
containing a structural protein of similar characteristics
as filoviral VP30 (i.e., extra nucleocapsid protein, inter-
action with the nucleoprotein) belong to the pneumoviri-
nae subfamily of Paramyxoviridae. Here, M2-1 repre-
sents an additional nucleocapsid protein besides N, P,
and L, which are conserved among the order Mono-
negavirales. M2-1 has been shown to interact with the
nucleoprotein of respiratory syncytial virus in intracellu-
lar inclusions and to act as a transcription elongation
and an antitermination factor (Collins et al., 1996; Garcia
et al., 1993; Hardy and Wertz, 1998). Recently, Hardy and
Wertz found that M2-1 is a phosphoprotein (Hardy and
Wertz, 2000). As with MBGV VP30, two forms of M2-1
were identified, differing in migration velocity in SDS–
PAGE. The phosphorylation sites within M2-1 have been
localized to the N-terminus where phosphoserine and
phosphothreonine were detected (Cuesta et al., 2000).
The phosphorylation seemed to influence the RNA-bind-
ing specificity of M2-1 (Cuesta et al., 2000). The function
of phosphorylation for the binding of M2-1 to N has not
been investigated.
Phosphorylation has previously been shown to be
important for the assembly of the nucleocapsid complex
of measles virus. Gombart et al. (1995) showed that the
nucleoprotein of measles virus which is assembled into
the nucleocapsids contains additional phosphoserine
residues compared to the nonassembled protein. This
result led to the conclusion that this additional phosphor-
ylation might be essential for the incorporation of the
nucleoprotein into measles virus nucleocapsids.
By phosphatase treatment of virion-associated VP30 it
was found that in addition to the majority of phosphory-
lated VP30, trace amounts of non- or weakly phosphor-
ylated VP30 were incorporated into the virions. Since our
data suggested that only phosphorylated VP30 is able to
be incorporated into progeny virus, it is unclear how
these molecules were bound to the virions. The pres-
ence of these molecules inside the virions could have
several reasons. Recently, we have found that VP30 is
able to build homooligomers whose formation is inde-
pendent of the phosphorylation state of the protein (un-
published data). Thus, it is possible that nonphosphory-
lated VP30 molecules are incorporated into the progeny
virions via oligomerization with phosphorylated mole-
cules.
Taken together, we have provided evidence that the
phosphorylation of VP30 takes place predominantly at
serine residues in the amino acid region 40–51. The
phosphorylation of serine residues 40 and 42 is essential
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179PHOSPHORYLATION OF MARBURG VIRUS VP30for the interaction of the protein with the aggregates of
NP, which are built of nucleocapsid-like particles. This
interaction is presumed to stand for one step in the
maturation of the MBGV nucleocapsid.
MATERIALS AND METHODS
Viruses and cell lines
C1008 cells, a cloned cell line of Vero cells (ATCC CRL
1586), Vero cells, and HeLa cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum. The Musoke strain of MBGV iso-
lated in 1980 in Kenya (Smith et al., 1982) was propa-
gated in C1008 cells and purified as described previously
(Funke et al., 1995). Monolayer cultures of HeLa cells
were used for all experiments with the recombinant vac-
cinia virus MVA-T7 containing the T7 RNA-polymerase
gene (Sutter et al., 1995). MVA-T7 was grown and titered
in chicken embryo fibroblasts. For all transfections, HeLa
cells were grown in six-well plates (7 cm2) using DMEM
containing 10% fetal calf serum.
Purification of 32P-labeled MBGV
Propagation, labeling, and purification of MBGV was
essentially done as described previously (Becker et al.,
1994), with the exception that the purification was carried
out in the presence of 1 mM phenylmethylsulfonyl fluo-
ride (PMSF), 50 mM sodium fluoride (NaF), and 100 mM
sodium-o-vanadate (NaV).
Molecular cloning of VP30 and VP30 mutants
For the expression of VP30 and the VP30 mutants, the
plasmids pGEM3zf1 (Promega) and pTM1 (Fuerst et al.,
1986) were used. In both plasmids, the inserted genes
are under the control of the T7 promoter.
Cloning of pGEM-VP30. The genomic RNA of MBGV,
which was used as template for reverse transcription-
polymerase chain reaction (PCR), was purified as de-
scribed previously (Mu¨hlberger et al., 1992). The open
reading frame of VP30 was amplified by reverse tran-
scription-PCR using the primers 100 (59 GAC GGA TCC
AAA ATG CAA CAA CCT CGC GGA AGA AGT CGA 39)
and 56 (59 GAC GGA TCC AGA GGT ACA AGT TGT TAA
TTA GAC ACT TAG 39), each containing a BamHI restric-
ion site (underlined). The resulting DNA fragment con-
ained the sequence of the VP30 gene from nucleotide
863–9983 of the MBGV RNA (EMBL data bank Acces-
ion No. Z12132). The PCR fragment was gel purified, cut
ith BamHI, and cloned into the BamHI site of the vec-
ors pGEM3zf1 and pTM1. The final plasmids were ver-
fied by sequencing and designated as pGEM-VP30 and
TM-VP30.
Cloning of the N- and C-terminal deletion mutants of
P30. The mutants were constructed according to stan-
ard molecular biological techniques using pGEM-VP30as template (digestion with suitable restriction endo-
nucleases, Klenow fill-in, or S1-nuclease digestion, rele-
gation) (Lo¨tfering et al., 1999).
Cloning of the mutant pGEM-VP3069–151.The coding re-
ion for amino acid 69–151 was amplified by PCR using
GEM-VP30 as template. The forward primer contained a
pnI restriction site followed by the nucleotides 9067–
087 of VP30 sequence. The reverse primer contained a
amHI site joined to the VP30 sequence 9292–9318. The
CR fragment was cloned into the plasmid pGEM3zf1.
Cloning of pTM-VP30FLAG and the VP30 substitution
mutants. pTM-VP30FLAG was constructed using pTM-VP30
as template by amplifying the open reading frame of
VP30 via PCR. The forward primer contained an NcoI
restriction site followed by the first 20 nucleotides of the
VP30 open reading frame. The reverse primer contained
a BamHI restriction site followed by the sequence en-
coding the FLAG epitope (Becker et al., 1998) joined to
the last 20 nucleotides of the open reading frame of
VP30. The PCR product was digested with BamHI and
NcoI and cloned into the vector pTM1. The influence of
the FLAG epitope on the intracellular localization of VP30
was checked by immunofluorescence analysis revealing
that the distribution of VP30 and VP30FLAG were identical
(data not shown).
Cloning of the VP30 substitution mutants with ex-
changed serine residues in the amino acid region 40–51
was performed using either the Quick Change site-di-
rected mutagenesis kit (Stratagene) or the Transformer
Site-directed Mutagenesis kit (Clontech). Exchange of
serine residues was performed either in a single step if
neighboring residues were to be replaced (e.g., S40 and
S42) or in sequential steps if more than two serine resi-
dues at more distant locations had to be exchanged. As
template, pTM-VP30FLAG was used.
nfection and transfection of HeLa cells
For phosphorylation state and phosphoamino acid
nalyses, subconfluent HeLa cells (5 3 105 cells in 7-cm2
wells) were infected with a multiplicity of infection of 3–5
plaque-forming units MVA-T7 per cell. At 1 h postinfec-
tion, cells were transfected with the respective plasmids
encoding NP, VP30, or VP30 mutants using the lipofectin
precipitation method (Felgner et al., 1994). The amounts
of plasmid DNA which were transfected are given in the
figure legends.
Metabolic labeling with [32P]orthophosphate or
35S]Promix
At 14 h posttransfection, HeLa cells were starved for
h with methionine- and cysteine-deficient DMEM or
hosphate-deficient Eagle’s minimum essential medium.
edium was removed, and cells were labeled for 2 h
ith 25 mCi of [35S]Promix (Amersham) or 3 h with 167
32mCi of [ Pi] (Amersham) in 1 ml starvation medium.
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180 MODROF ET AL.Immunoprecipitation and digestion with alkaline
phosphatase
After metabolic labeling, the medium was removed,
and cells were washed twice with ice-cold PBS supple-
mented with 1 mM PMSF, 50 mM NaF, and 100 mM NaV.
To determine the phosphorylation state of individual
VP30 mutants, 5 3 105 labeled cells were scraped into
0.5 ml ice-cold CoIP buffer [20 mM Tris–HCl, pH 7.5, 100
mM sodium chloride, 0.4% (w/v) deoxycholic acid, 1%
(w/v) NP-40, 25 mM iodoacetamide, 1 mM PMSF, 50 mM
NaF, 100 mM NaV, 17.5 mM EDTA]. Subsequently, cells
were sonicated, and cell debris was removed by centrif-
ugation for 5 min at 13,000 rpm. The supernatant was
incubated for 1 h at 4°C with 30 ml protein A-Sepharose,
which had been equilibrated in CoIP buffer. Sepharose
beads were precipitated at 13,000 rpm for 1 min at 4°C in
a tabletop centrifuge, and supernatants were further in-
cubated for 1 h with 2 ml of a polyclonal guinea pig
antiserum raised against MBGV VP30, or 1 ml mouse
monoclonal anti-FLAG M2 antibody (Sigma). Immune
complexes were bound to 25 ml protein A-Sepharose
uring 1 h at 4°C, precipitated, and washed five times
ith ice-cold CoIP buffer. Final pellets were resus-
ended in 50 ml of sample buffer [50 mM Tris–HCl, pH
.8, 4% (w/v) sodium dodecyl sulfate (SDS), 12% (w/v)
lycerol, 0.1 M dithiothreitol, 0.01% (w/v) saturated brom-
henol blue solution] and incubated for 5 min at 95°C.
en microliters of [32Pi]- or 20 ml of [
35S]Promix-labeled
samples were subjected to SDS–PAGE. The radioactive
signals were visualized by exposing the dried gels to a
BioImager plate and quantified using the BioImaging
Analyzer Fuji BAS-1000 with the Raytest TINA software.
For alkaline phosphatase treatment, immune com-
plexes bound to Sepharose were resuspended in 100 ml
of dephosphorylation buffer (50 mM Tris, 0,1 mM EDTA,
pH 8.5) and treated overnight at 16°C with 60 U calf
intestine phosphatase (CIP, Roche).
For phosphoamino acid analyses, 2.4 3 106 meta-
olically labeled HeLa cells (either [32Pi] or [
35S]Pro-
ix) were scraped into 1-ml ice-cold CoIP buffer. Im-
unoprecipitation was carried out as described above
sing triple volumes of antiserum and protein
-Sepharose, respectively. Immune complexes were
luted three times in a total volume of 125 ml sample
buffer (23 50 ml and 13 25 ml) before being subjected
to SDS–PAGE.
Phosphoamino acid analysis [two-dimensional thin-
layer chromatography (2D-TLC)]
The determination of the type of phosphoamino acids
was performed as described by Lo¨tfering et al. (1999).riefly, either virion-associated or recombinant VP30 wasmetabolically labeled and purified as described above.
Immune complexes were separated by SDS–PAGE and
blotted onto Immobilon membranes. The phosphorylated
VP30 was cut out and partially hydrolyzed using hydro-
chloric acid. The hydrolysates were spotted onto thin-
layer chromatography plates and cochromatographed
together with standard phosphoamino acids. The radio-
active signals were visualized by exposing the thin-layer
chromatography plates to a BioImager plate and quanti-
fied using the BioImaging Analyzer Fuji BAS-1000 with
the Raytest TINA software. The standard phosphoamino
acids were detected by ninhydrine.
Indirect immunofluorescence analysis
HeLa cells were cultured on glass coverslips to 50%
confluence and infected with MVA-T7 as described
above. At 1 h p.i., cells were transfected with plasmids
encoding NP (pT-NP) (Mu¨hlberger et al., 1998) and VP30
or NP and the VP30 mutants. The amount of transfected
plasmid DNA encoding the VP30 mutants is given in the
figure legends and was previously determined by West-
ern blot to receive equal expression levels. At 8–12 h
posttransfection, cells were fixed for 5 min with 3% para-
formaldehyde (PFA) at room temperature (RT). Cells were
then rinsed two times with PBS and incubated with 0.1 M
glycine for 10 min at RT. Thereafter, plasma membranes
were permeabilized with 0.2% of Triton X-100 for 20 min.
Samples were washed again with PBS and incubated for
1 h at room temperature with the respective antibodies,
as indicated in the figure legends. Subsequently, cells
were washed three times with PBS and stained with the
secondary antibodies for 1 h at room temperature (the
secondary antibodies are indicated in the figure leg-
ends). Finally, cells were washed three times with PBS,
dipped into double distilled H2O, covered with mounting
medium, and examined using a fluorescence micro-
scope (Axiomat, Zeiss).
Formic acid treatment
Immunoprecipitated [35S]Promix- or [32Pi]-labeled
P30, still bound to the protein A-Sepharose pellets was
reated with 500 ml of 70% formic acid for 60 h at 37°C.
he formic acid was then removed by Speed Vac cen-
rifugation, and the pellets were resuspended and dried
hree times with 300, 100, and 50 ml double-distilled H2O,
respectively. Samples were resuspended in sample
buffer and separated by SDS–PAGE at room tempera-
ture.
Electron microscopic analysis
HeLa cells were infected with MVA-T7 and transfected
with plasmids encoding NP and VP30 or a VP30 mutant.
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181PHOSPHORYLATION OF MARBURG VIRUS VP30At 16 h p.i., cells were washed once with PBS and fixed
for 1 h with 4% PFA. Cells were further prepared for
electron microscopy as described previously (Kolesni-
kova et al., 2000).
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